Saturday 21 December 2024
Internal Reference Number: FOI_7276
Date Request Received: 04/07/2023 00:00:00
Date Request Replied To: 02/08/2023 00:00:00
This response was sent via: By Email
Request Summary: Chitin/Chitosan product(s)
Request Category: Private Individuals
| Question Number 1: Q1a) Is any of the product(s) purchased/used in your hospital contain Chitin/Chitosan (e.g. surgical sutures, materials in wound healing/tissue engineering/dentistry/drug delivery)? ☐Yes ☐No If the answer to Q1a is Yes then skip to Q2a. If the answer to Q1a is No then: Q1b) Do you plan on utilizing products containing Chitin/Chitosan in the next two years? ☐Yes ☐No If the answer to Q1b is No, you may skip the rest of the questionnaire. If the answer to Q1b is Yes, answer Q2a and then you may skip the rest of the questionnaire. | |
| Answer To Question 1: Section 12 exemption notice applied Pharmacy response - Pharmacy are unable to answer this question as it would entail looking at 3000 plus lines that Pharmacy stock individually and this would take well over the 18 hours allowed. Procurement response - Procurement have worked with our Clinical Procurement Specialist (CPS) and Procurement do not hold data identifying these materials at any of the Trusts, so without undertaking a manual inspection of products, which would be over 18 hours | |
| Question Number 2: Q2a) What product(s) do you have in the hospital (or intend to purchase) that contains Chitin/Chitosan? Q2b) For each product listed in response to Question Q2a, could you please provide the following details: - The product's brand name. - The purpose of the product and in which department it is used. - The approximate volume of the product used/purchased over the last financial year (1st April 2022 – 31st March 2023). | |
| Answer To Question 2: Please see answer to Q1 | |
| Question Number 3: Q3) Has the hospital received any complaints or filed any cases of side effects from using the Chitin/Chitosan product(s) mentioned above? If so, please provide detail of the following: a) Number of cases in years 2020, 2021, 2022 and 2023 b) description of the most three common side effects c) Which product(s) caused the most commonly seen side effects | |
| Answer To Question 3: Please see answer to Q1 | |
| Question Number 4: Q4) Is there any limitation(s), certification(s), or regulatory requirement(s) that are bounded when utilizing Chitin/Chitosan in the hospital (i.e. ISO standards or Ethics, etc)? If so, please specify. | |
| Answer To Question 4: Please see answer to Q1 | |
| Question Number 5: Q5) Is the hospital currently or will be promoting any new products containing chitin or chitosan? | |
| Answer To Question 5: Please see answer to Q1 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
